Glucagon is a hormone that signals the liver to release glucose into the bloodstream. It's typically given by injection to counteract severe hypoglycemia in people who have diabetes.

Altimmune’s pemvidutide failed to significantly improve fibrosis in MASH patients in a Phase IIb study. The biotech crashed ...

A dozen volunteers with severe type 1 diabetes showed clear improvements in their condition 12 months after receiving a ...

Testing their glucagon-packed micelles in lab experiments, the researchers found that they disassembled and released glucagon only in liquid environments that mimicked hypoglycemia in humans and ...

There’s some new guidance on treating hypoglycemia, or low blood sugar, in long-term care communities. It’s specifically geared for healthcare workers, though anyone who is a caregiver for ...

On readmission, in January, 1965, no new physical findings were evident, and it was not known whether the zinc glucagon was inactive or the worsening condition was due to progression of the disease.

A new study led by Ananda Basu, M.D., used novel non-radioactive, stable glucagon tracers for the first time to characterize glucagon metabolism in humans with and without Type 1 diabetes, providing ...

A new class of medications — called glucagon-like peptide 1 receptor agonists, or GLP-1s — has taken the country by storm because these drugs seem to make weight loss more effortless.

On readmission, in January, 1965, no new physical findings were evident, and it was not known whether the zinc glucagon was inactive or the worsening condition was due to progression of the disease.